<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00346814</url>
  </required_header>
  <id_info>
    <org_study_id>APEC-001</org_study_id>
    <nct_id>NCT00346814</nct_id>
  </id_info>
  <brief_title>Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome</brief_title>
  <official_title>Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asociación para Evitar la Ceguera en México</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asociación para Evitar la Ceguera en México</source>
  <brief_summary>
    <textblock>
      Purpose:Retinopathy of prematurity (ROP) continues tobe a major cause of blindness in
      children. Although ablation of the retina with laser or cryotherapy reduces the incidence of
      blindness by suppressing the neovascular phase of ROP the visual outcomes after treatment are
      often poor. Vascular endothelial growth factor(VEGF) has an important role in the
      pathogenesis of ROP and inhibition of VEGF expression in the neovascular phase might prevent
      destructive neovascularization in ROP. The aim of this study is to determine the safety and
      efficacy of intravitreal bevacizumab in the treatment of retinopathy of prematurity
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2006</start_date>
  <completion_date type="Anticipated">November 2006</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical appearance</measure>
  </primary_outcome>
  <condition>Retinopathy of Prematurity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravitreal injection</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Retinopathy of prematurity stages III, IV and V in which we can not treat with laser o
             cryotherAPY

        Exclusion Criteria:

          -  PATIENTS THAT COULD BE TREATED WITH CRYOTHERAPY OR LASER
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Martínez-Castellanos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APEC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hugo Quiroz-Mercado, MD</last_name>
    <phone>525510841400</phone>
    <phone_ext>1171</phone_ext>
    <email>retinamex@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria A Martínez-Castellanos, MD</last_name>
    <phone>525510841400</phone>
    <phone_ext>1171</phone_ext>
    <email>retinamex@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asociación para Evitar la Ceguera en México Hospital &quot;Luis Sanchez Bulnes&quot;</name>
      <address>
        <city>Mexico City</city>
        <state>Mexico DF</state>
        <zip>04030</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria A Martinez-Castellanos, MD</last_name>
      <phone>525510841400</phone>
      <phone_ext>1171</phone_ext>
      <email>retinamex@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Maria Martinez-Castellanos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hugo A Quiroz-Mercado, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Myriam L Hernandez-Rojas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jans Fromow-Guerra, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>June 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2006</study_first_submitted>
  <study_first_submitted_qc>June 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2006</study_first_posted>
  <last_update_submitted>June 28, 2009</last_update_submitted>
  <last_update_submitted_qc>June 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2009</last_update_posted>
  <keyword>Retinopathy of prematurity</keyword>
  <keyword>antiangiogenic therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Retinopathy of Prematurity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Angiogenesis Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

